Immunomedics Inc. said that Russell C. McLauchlan hasresigned as president and chief operating officer and hasrelinquished his board seat. The company did not disclosereasons for his departure. Also, A.E. Cohen, retired president ofMerck Sharp & Dohme International and senior vice presidentof Merck & Co. Inc., has been elected to the board. The Warren,N.J., company (NASDAQ:IMMU) develops products for detectingcancer and infectious diseases.
Bioject has named Richard Hollis chief operating officer. He wasexecutive vice president of marketing and sales. The Portland,Ore., company (NASDAQ:BJCTF) markets a system that is able toinject medication through the skin without a needle.
Advanced Tissue Sciences Inc. of La Jolla, Calif., named threenew vice presidents. Jean-Jacques Bienaime, who directedmarketing of cardiopulmonary products at Genentech Inc., hasbeen named vice president of sales and marketing. TerryGibson, previously vice president of operations at MeridianDiagnostics, was named vice president of operations. AndMitchell R. Woodbury, currently senior vice president, generalcounsel and corporate secretary at Intermark Inc., was namedvice president, general counsel. Advanced Tissue Sciences(NASDAQ:ATISA) is a tissue engineering company.
CytRx Corp. of Norcross, Ga., named Lucine E. Beauchard vicepresident of business development/marketing. She heldbusiness development and marketing positions at McNeilPharmaceutical, a division of Johnson & Johnson, and Rhone-Poulenc Rorer. CytRx (NASDAQ:CTRX) is developing therapeuticsincorporating copolymers.
Neurex Corp. has named Robert R. Luther vice president ofdevelopment, and Bradford M. Wait vice president of financeand administration, chief financial officer and treasurer. Lutherwas division director of cardiovascular drug R&D at AbbottLaboratories. Wait was vice president of finance and CFO atPixar, a software company. Also, John F. Chappell, founder andpresident of Plexus Ventures Inc., an investment firm, has beenelected to the board of the Menlo Park, Calif., company, whichis developing treatments for disorders and diseases of thebrain and central nervous system.
ImmunoPharmaceutics named Seymour Mong vice presidentfor biotechnology. Mong held posts at Fujisawa (USA INC.), aswell as SmithKline Beckman. The San Diego company, which isfocused on peptide structure-based drug design, is 48 percentowned by Synbiotics Corp. (NASDAQ:SBIO).
(c) 1997 American Health Consultants. All rights reserved.